B H Mitlak

Summary

Affiliation: Eli Lilly and Company
Country: USA

Publications

  1. ncbi In search of optimal long-term female hormone replacement: the potential of selective estrogen receptor modulators
    B H Mitlak
    Lilly Research Laboratories, Eli Lilly and Company, Indianapolis, Ind 46285, USA
    Horm Res 48:155-63. 1997
  2. ncbi Pharmacogenomics in endocrinology
    Richard D Hockett
    Eli Lilly and Company, Lilly Corporate Center, Indianapolis, IN 46285, USA
    J Clin Endocrinol Metab 87:2495-9. 2002
  3. ncbi Recommendations for the registration of agents to be used in the prevention and treatment of glucocorticoid-induced osteoporosis: updated recommendations from the Group for the Respect of Ethics and Excellence in Science
    Eric C Abadie
    Department of Public Health, Epidemiology, and Health Economics, , , Belgium
    Semin Arthritis Rheum 35:1-4. 2005
  4. ncbi Selective estrogen receptor modulators: a look ahead
    B H Mitlak
    Indiana University School of Medicine, Indianapolis, USA
    Drugs 57:653-63. 1999
  5. ncbi Parathyroid hormone as a therapeutic agent
    Bruce H Mitlak
    Medical Advisor, Eli Lilly and Company Lilly Corporate Center, Indianapolis, IN 46285, USA
    Curr Opin Pharmacol 2:694-9. 2002
  6. ncbi Osteosarcoma and teriparatide?
    Kristine D Harper
    J Bone Miner Res 22:334. 2007
  7. ncbi Comments on Initial experience with teriparatide in the United States
    Kristine D Harper
    Curr Med Res Opin 22:1927. 2006
  8. ncbi Sustained nonvertebral fragility fracture risk reduction after discontinuation of teriparatide treatment
    Richard Prince
    Department of Endocrinology and Diabetes and University of Western Australia, Sir Charles Gairdner Hospital, Nedlands, Australia
    J Bone Miner Res 20:1507-13. 2005
  9. ncbi Sustained vertebral fracture risk reduction after withdrawal of teriparatide in postmenopausal women with osteoporosis
    Robert Lindsay
    Regional Bone Center, Helen Hayes Hospital, West Haverstraw, NY 10993, USA
    Arch Intern Med 164:2024-30. 2004
  10. ncbi Recombinant human parathyroid hormone (1-34) [teriparatide] improves both cortical and cancellous bone structure
    Yebin Jiang
    Osteoporosis and Arthritis Research Group, Department of Radiology, University of California, San Francisco, California 94143 0628, USA
    J Bone Miner Res 18:1932-41. 2003

Collaborators

Detail Information

Publications11

  1. ncbi In search of optimal long-term female hormone replacement: the potential of selective estrogen receptor modulators
    B H Mitlak
    Lilly Research Laboratories, Eli Lilly and Company, Indianapolis, Ind 46285, USA
    Horm Res 48:155-63. 1997
    ..Large-scale clinical testing currently in progress for raloxifene, and soon to begin for other SERMs, will evaluate this important potential...
  2. ncbi Pharmacogenomics in endocrinology
    Richard D Hockett
    Eli Lilly and Company, Lilly Corporate Center, Indianapolis, IN 46285, USA
    J Clin Endocrinol Metab 87:2495-9. 2002
  3. ncbi Recommendations for the registration of agents to be used in the prevention and treatment of glucocorticoid-induced osteoporosis: updated recommendations from the Group for the Respect of Ethics and Excellence in Science
    Eric C Abadie
    Department of Public Health, Epidemiology, and Health Economics, , , Belgium
    Semin Arthritis Rheum 35:1-4. 2005
    ..Demonstration of antifracture efficacy should have been previously demonstrated in PMO...
  4. ncbi Selective estrogen receptor modulators: a look ahead
    B H Mitlak
    Indiana University School of Medicine, Indianapolis, USA
    Drugs 57:653-63. 1999
    ..The clinical success of SERMs has set the stage for a variety of drug therapies based on selective modulation of nuclear receptor activity...
  5. ncbi Parathyroid hormone as a therapeutic agent
    Bruce H Mitlak
    Medical Advisor, Eli Lilly and Company Lilly Corporate Center, Indianapolis, IN 46285, USA
    Curr Opin Pharmacol 2:694-9. 2002
    ..The occurrence of osteosarcoma in long-term toxicology studies in rats is briefly reviewed...
  6. ncbi Osteosarcoma and teriparatide?
    Kristine D Harper
    J Bone Miner Res 22:334. 2007
  7. ncbi Comments on Initial experience with teriparatide in the United States
    Kristine D Harper
    Curr Med Res Opin 22:1927. 2006
  8. ncbi Sustained nonvertebral fragility fracture risk reduction after discontinuation of teriparatide treatment
    Richard Prince
    Department of Endocrinology and Diabetes and University of Western Australia, Sir Charles Gairdner Hospital, Nedlands, Australia
    J Bone Miner Res 20:1507-13. 2005
    ..CONCLUSIONS: While the study design is observational, the results support a sustained effect of teriparatide in reducing the risk of nonvertebral fragility fractures up to 30 months after discontinuation of treatment...
  9. ncbi Sustained vertebral fracture risk reduction after withdrawal of teriparatide in postmenopausal women with osteoporosis
    Robert Lindsay
    Regional Bone Center, Helen Hayes Hospital, West Haverstraw, NY 10993, USA
    Arch Intern Med 164:2024-30. 2004
    ..Teriparatide (recombinant human parathyroid hormone [1-34]) reduces fracture risk in postmenopausal women with osteoporosis. We assessed the safety and incidence of new vertebral fractures after withdrawal of teriparatide...
  10. ncbi Recombinant human parathyroid hormone (1-34) [teriparatide] improves both cortical and cancellous bone structure
    Yebin Jiang
    Osteoporosis and Arthritis Research Group, Department of Radiology, University of California, San Francisco, California 94143 0628, USA
    J Bone Miner Res 18:1932-41. 2003
    ....
  11. ncbi Clinical evaluation of medicinal products for acceleration of fracture healing in patients with osteoporosis
    Jörg Goldhahn
    Schulthess Clinic Zurich and Clinical Priority Program Fracture Fixation in Osteoporotic, Bone of AO Foundation, Davos, Switzerland
    Bone 43:343-7. 2008
    ..The study design should be randomized, parallel, double-blind, and placebo-controlled, and all fracture subjects should receive a standardized method of fracture fixation, defined as Standard of Care...